Shares of Cesca Therapeutics’ (NASDAQ: KOOL) are up 12% mid-morning on promising data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers. The study, entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series,” was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute. Results from the 24 patient study were published in the peer-reviewed Journal of Biomedical Science. During the study, 24 patients with one wound or ulcer were treated with a single dose of PRP injections around the wound together with a topical administration of autologous platelet gel. Healing of the wound or ulcer was observed in patients as early as 4 weeks after the PRP treatment with a mean healing time of 8.2 weeks. All patients demonstrated healing of the wound/ulcer, with 17 patients showing a 90% reduction in wound size and 3 patients showing an 80-90% reduction over the course of the 24 week follow-up. “As we continue to strengthen our team and evaluate Cesca’s clinical pipeline, these additional data points serve as useful litmus tests to determine the most valuable growth opportunities for the company,” Cesca interim chief executive officer Dr. Chris Xu stated in the news release.
To view the full press release, visit: http://nnw.fm/88kOG
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The company is also engaged in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include The SurgWerks™ System (in development) — a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases; The CellWerks™ System (in development) — a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; The AutoXpress® System (AXP®) — a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; The MarrowXpress™ System (MXP™) — a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; The BioArchive® System — an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use; and manual bag sets for use in the processing and cryogenic storage of cord blood. For more information visit www.cescatherapeutics.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer